Progress of immunotherapy of cholangiocarcinoma
10.3760/cma.j.cn113884-20200226-00094
- VernacularTitle:胆管癌的免疫治疗进展
- Author:
Xuebing SHI
;
Jinghan WANG
;
Xiaoqing JIANG
- From:
Chinese Journal of Hepatobiliary Surgery
2021;27(1):77-80
- CountryChina
- Language:Chinese
-
Abstract:
Cholangiocarcinoma (CCA) is a group of solid tumors with high malignant degree and poor prognosis. Surgical resection has still been the main therapy options. Targeting therapy and immunotherapy are the main anti-tumor methods that have been paid more and more attention in recent years, especially immunotherapy. The tumor microenvironment of CCA is complex, which encompasses not only interstitial and endothelial cells, but also a large number of immune cells. In addition, the innate and adaptive immune systems also play a role. This article summarizes the immune-related studies of cholangiocarcinoma and the latest clinical trials of immunotherapy.
